Bone turnover in young hypoestrogenic women on hormonal therapy.
OBJECTIVE
To compare the biochemical markers of bone turnover in hypoestrogenic women who had been on the standard dosage of Premarin 0.625 mg to that of the age-matched women who were menstruating spontaneously.


METHODS
Chinese women between 25 and 40 years of age with a diagnosis of hypoestrogenism who had been on Premarin 0.625 mg daily for more than 1 year were recruited. The control group comprised age- and parity-matched women who had proven ovulation by mid-cycle serum luiteinising hormone surge. Serum osteocalcin and serum pyridinoline crosslink, markers of bone formation and resorption, respectively, were measured by enzyme-linked immunosorbent assays.


RESULTS
Twenty hypoestrogenic Chinese patients with a mean age of 36.2 were recruited as the study group. The same number of controls was recruited. There were no smokers in either group. The body weight, body height and body mass indices were comparable between the two groups. Both biochemical markers of bone metabolism did not differ between the two groups.


CONCLUSIONS
The average bone turn-over rate in young hypoestrogenic Chinese women on Premarin 0.625 mg/day was similar to that of normal menstruating women.
Chan
Carina C W
CC
Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China. cwcchan@graduate.hku.hk
Tang
Oi-Shan
OS
Lau
Winnie N T
WN
Tang
Grace W K
GW
D000328:Adult; D044466:Asian People; D015415:Biomarkers; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016723:Bone Remodeling / Q000187:drug effects*; D001862:Bone Resorption / Q000188:drug therapy; D016022:Case-Control Studies; D024042:Collagen Type I / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004967:Estrogens / Q000172:deficiency*; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015675:Osteocalcin / Q000097:blood; D010024:Osteoporosis / Q000517:prevention & control; D010455:Peptides / Q000097:blood; D016896:Treatment Outcome
D015415:Biomarkers; D024042:Collagen Type I; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin